866-997-4948(US-Canada Toll Free)

Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 59 Pages

Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H1 2017

Summary

Beta Nerve Growth Factor (Beta NGF or NGF) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The latest report Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H1 2017, outlays comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Beta Nerve Growth Factor (Beta NGF or NGF) - Nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It inhibits metalloproteinase dependent proteolysis of platelet glycoprotein VI. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 5 and 1 respectively. Report covers products from therapy areas Central Nervous System, Ophthalmology, Genito Urinary System And Sex Hormones, Metabolic Disorders and Toxicology which include indications Osteoarthritis Pain, Alzheimer's Disease, Cancer Pain, Low Back Pain, Pain, Chemotherapy Induced Peripheral Neuropathy, Chronic Pain, Diabetic Neuropathy, Huntington Disease, Interstitial Cystitis (Painful Bladder Syndrome), Keratitis, Mild Cognitive Impairment, Optic Nerve Injury, Peripheral Nerve Injury and Post-Operative Pain.

Furthermore, this report also reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Beta Nerve Growth Factor (Beta NGF or NGF)
- The report reviews Beta Nerve Growth Factor (Beta NGF or NGF)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Beta Nerve Growth Factor (Beta NGF or NGF)targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Beta Nerve Growth Factor (Beta NGF or NGF)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Beta Nerve Growth Factor (Beta NGF or NGF)development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Beta Nerve Growth Factor (Beta NGF or NGF) - Overview
Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development
Amgen Inc
Astellas Pharma Inc
Fujimoto Pharmaceutical Corp
Krenitsky Pharmaceuticals Inc
MedImmune LLC
NsGene A/S
Pfizer Inc
Regeneron Pharmaceuticals Inc
Serometrix LLC
Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles
AS-288640100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-6294 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fasinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulranumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate NGF for Optic Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-544 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-7352 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NsG-0202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Neurotrophic Keratitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NGF for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Products
Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products
Beta Nerve Growth Factor (Beta NGF or NGF) - Product Development Milestones
Featured News & Press Releases
Oct 17, 2016: Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs
May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
Mar 31, 2016: Janssen Announces Discontinuation of Fulranumab Phase 3 Development Program in Osteoarthritis Pain
Mar 23, 2015: Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab
Mar 12, 2012: FDA Panel Recommends Development Of NGF Inhibitors
Feb 09, 2011: CeNeRx Receives FDA IND Approval For CXB909
Dec 27, 2010: FDA Halts Development Of Regenerons Pain Drug
Jul 19, 2010: Pfizer Suspends Chronic Pain Studies In Tanezumab Clinical Trial Program
Jun 23, 2010: Pfizer Suspends Osteoarthritis Clinical Program For Tanezumab
May 12, 2010: Regeneron Provides Initial Data On REGN475
Feb 16, 2010: Pending Results of Phase Ib Trial for Nsg0202 for Alzheimer's Disease in 2010
Nov 15, 2008: Nsgene Has Announced That Six Patients with Alzheimer's Disease Have Now Been Implanted with Its Novel Biodelivery Product Nsg 0202
Oct 24, 2008: Krenitsky Pharmaceuticals Wants Out Of Deal With Keryx
Dec 17, 2007: NsGene First To Implant Genetically Modified Cells Into Patients' Brains
Dec 12, 2007: Nsgene A/S Begins Phase Ib Clinical Trial with Nsg0202 for the Treatment of Alzheimers Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Amgen Inc, H1 2017
Pipeline by Astellas Pharma Inc, H1 2017
Pipeline by Fujimoto Pharmaceutical Corp, H1 2017
Pipeline by Krenitsky Pharmaceuticals Inc, H1 2017
Pipeline by MedImmune LLC, H1 2017
Pipeline by NsGene A/S, H1 2017
Pipeline by Pfizer Inc, H1 2017
Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Pipeline by Serometrix LLC, H1 2017
Dormant Projects, H1 2017
Discontinued Products, H1 2017

List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Top 10 Indications, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *